The pharmaceutical company seeks to consolidate its leadership in Latin America by offering high-quality generic medications.
Eurofarma, a pharmaceutical company present in 22 countries in Latin America, the United States and some African countries, announced the return of the Genfar brand for Guatemala and Central America.
After a brief period of absence (2019-2023), the brand returns to the region, initially in Guatemala, Panama, Costa Rica and Honduras, with the aim of continuing to provide medicines of the highest quality and effectiveness to millions of people in the region.
In 2023, Eurofarma announced the acquisition of 100% of the representative shares of Genfar, the largest investment that the group has made in its history and an important consolidation of Eurofarma in the region. Genfar will be Eurofarma's generic brand for all of Latin America, except for the Brazilian market. After the relaunch in the first four countries in Central America, Genfar's expansion will continue in 2025 in the Dominican Republic, El Salvador and Nicaragua.
Genfar has operations in Colombia, Ecuador and Peru, with a production plant in Cali. The company has more than 600 collaborators and offers a robust portfolio of more than 150 molecules and 600 SKUs. In 2023, Genfar produced more than 1 million products, distributed in 8 countries.
The beginning of Genfar's regional expansion marks the consolidation in Latin America of Eurofarma, a company with 52 years of history that is the leader in sales of prescription products in the region and in Brazil, where it also occupies second place in generics.
"We seek to promote timely access to health and quality of life, aligned with our purpose of expansion and operations in Central America. With the return of Genfar to the region, in these 4 countries, we managed to increase the portfolio of generic products almost three times. of Eurofarma compared to last year, offering more options for patients and greater coverage of therapeutic areas,” said Agustin Vincent, general manager of Genfar.
“Guatemala, where we already have a factory, is a strategic point for our expansion and for the arrival of Genfar to the Central American region,” commented Francisco Pérez, general manager of Eurofarma in Central America and the Caribbean.
“This union strengthens the company's commitment to offering innovative and high-quality products to more people around the world, which are our priorities along with sustainable growth,” concluded Rosalba Pantoja, executive director of International Operations at Eurofarma.
Genfar's portfolio covers a wide range of therapeutic areas, with both prescription and over-the-counter products. Among the categories of medicines that will be marketed are analgesics, anti-inflammatory, dermatological and systemic anti-infectives, as well as products for the nervous system, genitourinary system and the cardiovascular system.
